NYSE:MED MEDIFAST (MED) Stock Price, News & Analysis $13.50 -0.25 (-1.82%) Closing price 03:59 PM EasternExtended Trading$13.50 0.00 (-0.01%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About MEDIFAST Stock (NYSE:MED) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MEDIFAST alerts:Sign Up Key Stats Today's Range$13.46▼$13.8550-Day Range$12.48▼$15.2252-Week Range$11.57▼$21.98Volume145,054 shsAverage Volume207,095 shsMarket Capitalization$148.37 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingHold Company Overview Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland. Read More MEDIFAST Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreMED MarketRank™: MEDIFAST scored higher than 64% of companies evaluated by MarketBeat, and ranked 71st out of 150 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingMEDIFAST has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMEDIFAST has received no research coverage in the past 90 days.Read more about MEDIFAST's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth200.00% Earnings GrowthEarnings for MEDIFAST are expected to grow by 200.00% in the coming year, from $0.51 to $1.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MEDIFAST is -20.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MEDIFAST is -20.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMEDIFAST has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about MEDIFAST's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.30% of the float of MEDIFAST has been sold short.Short Interest Ratio / Days to CoverMEDIFAST has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in MEDIFAST has recently increased by 18.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMEDIFAST does not currently pay a dividend.Dividend GrowthMEDIFAST does not have a long track record of dividend growth. Sustainability and ESG2.0 / 5Environmental Score-4.00 Percentage of Shares Shorted21.30% of the float of MEDIFAST has been sold short.Short Interest Ratio / Days to CoverMEDIFAST has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in MEDIFAST has recently increased by 18.62%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 8 news articles for MEDIFAST this week, compared to 3 articles on an average week.Search Interest3 people have searched for MED on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added MEDIFAST to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, MEDIFAST insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,003.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of MEDIFAST is held by insiders.Percentage Held by Institutions95.51% of the stock of MEDIFAST is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MEDIFAST's insider trading history. Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MEDIFAST and its competitors with MarketBeat's FREE daily newsletter. Email Address MED Stock News HeadlinesMedifast Announces Second Quarter 2025 Financial ResultsAugust 4 at 4:05 PM | businesswire.comMedifast (MED) Reports Q2: Everything You Need To Know Ahead Of EarningsAugust 3 at 3:34 AM | msn.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.August 4 at 2:00 AM | Brownstone Research (Ad)Medifast (MED) Projected to Post Earnings on MondayAugust 2 at 2:15 AM | americanbankingnews.comMedifast (MED) Earnings Report: Anticipated Decline in Q2 PerformanceAugust 1 at 10:09 PM | gurufocus.comMedifast Q2 2025 Earnings PreviewAugust 1 at 3:19 PM | seekingalpha.com3 Unpopular Stocks We Keep Off Our RadarJuly 30, 2025 | msn.comHead to Head Analysis: Cuisine Solutions (OTCMKTS:CUSI) & Medifast (NYSE:MED)July 27, 2025 | americanbankingnews.comSee More Headlines MED Stock Analysis - Frequently Asked Questions How have MED shares performed this year? MEDIFAST's stock was trading at $17.62 at the beginning of the year. Since then, MED shares have decreased by 23.4% and is now trading at $13.50. How were MEDIFAST's earnings last quarter? MEDIFAST INC (NYSE:MED) released its quarterly earnings data on Monday, August, 4th. The specialty retailer reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.26. MEDIFAST had a negative net margin of 1.29% and a positive trailing twelve-month return on equity of 6.63%. Read the conference call transcript. Who are MEDIFAST's major shareholders? Top institutional investors of MEDIFAST include Peapod Lane Capital LLC (0.79%), SummerHaven Investment Management LLC (0.39%), Allianz Asset Management GmbH (0.20%) and Chickasaw Capital Management LLC (0.13%). Insiders that own company stock include Daniel R Chard, Scott Schlackman, Andrea B Thomas, Jeffrey J Brown and Constance J Hallquist. View institutional ownership trends. How do I buy shares of MEDIFAST? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MEDIFAST own? Based on aggregate information from My MarketBeat watchlists, some other companies that MEDIFAST investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AU Optronics (AUOTY). Company Calendar Today8/04/2025Last Earnings8/04/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry FOOD - MISC/DIVERSIFIED Sub-IndustryPersonal Products Current SymbolNYSE:MED CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees870Year FoundedN/APrice Target and Rating Average Price Target for Medifast$16.50 High Price Target$16.50 Low Price Target$16.50 Potential Upside/Downside+22.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.65) Trailing P/E RatioN/A Forward P/E Ratio26.47 P/E GrowthN/ANet Income$2.09 million Net Margins-1.29% Pretax Margin-1.34% Return on Equity6.63% Return on Assets4.81% Debt Debt-to-Equity RatioN/A Current Ratio3.52 Quick Ratio2.87 Sales & Book Value Annual Sales$602.46 million Price / Sales0.25 Cash Flow$2.88 per share Price / Cash Flow4.68 Book Value$19.21 per share Price / Book0.70Miscellaneous Outstanding Shares10,990,000Free Float10,672,000Market Cap$148.37 million OptionableOptionable Beta0.80 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NYSE:MED) was last updated on 8/4/2025 by MarketBeat.com Staff From Our Partners[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut with the old (A.I.) - In with the new (E.I.)One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEDIFAST INC Please log in to your account or sign up in order to add this asset to your watchlist. Share MEDIFAST With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.